The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes
Open accessAbstract
An open-label, first-in-human phase 1/2 study is being conducted to evaluate the safety and efficacy of pancreatic endoderm cells (PECs) implanted in non-immunoprotective macroencapsulation devices for the treatment of type 1 diabetes. We report an analysis on 1 year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen. Implants were well tolerated with no teratoma formation or severe graft-related adverse events. After implantation, patients had increased fasting C-peptide levels and increased glucose-responsive C-peptide levels and developed mixed meal-stimulated C-peptide secretion. There were immunosuppression-related transient increases in circulating regulatory T cells, PD1 high T cells, and IL17A+CD4+ T cells. Explanted grafts contained cells with a mature β cell phenotype that were immunoreactive for insulin, islet amyloid polypeptide, and MAFA. These data, and associated findings (Shapiro et al., 2021), are the first reported evidence of meal-regulated insulin secretion by differentiated stem cells in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon graft removal, a majority of these graft-derived cells immunostained for the general endocrine marker chromogranin A (CHGA).”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells, these clinical trials have demonstrated that facilitating host-derived vascularization into the graft promoted long-term endocrine cell survival and function in humans.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other regions of the device, however, host fibroblasts were the predominant cell type, resulting in the deposition of fibrotic tissue rather than host-derived vasculature.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells, these clinical trials have demonstrated that facilitating host-derived vascularization into the graft promoted long-term endocrine cell survival and function in humans.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As intended, the porous design promoted the growth of host-derived blood vessels inside the device, and this phenomenon was more prominent in regions containing the graft-derived cells.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ViaCyte clinical trial, the explanted grafts after months in vivo were observed to be highly heterogenous between patients since the cells were transplanted as pancreatic progenitors and allowed to finish differentiating in vivo.33,35”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, while there were regions of C-peptide positive β-like cells, a majority of these endocrine cells stained for the α cell marker glucagon. Ductal cells and rare acinar cells were also observed.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the transplanted PEC-Encap product was well tolerated with few adverse effects, the trial was halted due to insufficient functional product engraftment.33”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“these macroencapsulation devices can also promote fibrosis around the implant, further preventing nutrient diffusion.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, these studies did not detect any serious safety concerns related to the transplanted cells, such as tumor formation.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“An ongoing clinical trial was started in 2017 at seven sites to test this device (clinicaltrials.gov: NCT03163511), and the first round of results have recently been published.33,35”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While some endocrine cells were observed, fibrosis around the capsule resulted in graft loss, and no insulin secretion from the device was detected.33,34”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“They demonstrated glucose responsive C-peptide production 6-9 months post-transplant as the grafted cells matured from pancreatic progenitors into pancreatic endocrine cells.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationThe Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells
D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O., Agulnick, A. D., Smart, N. G., Moorman, M. A., KROON, E. J., Carpenter, M. K., & Baetge, E. E. (2006) · Nature Biotechnology · doi:10.1038/nbt1259 · Cited by 1,913
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843
Efficient differentiation of human embryonic stem cells to definitive endoderm
D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., & Baetge, E. E. (2005) · Nature Biotechnology · doi:10.1038/nbt1163 · Cited by 1,730
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Self-citationRituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Insulin Production by Human Embryonic Stem Cells
Assady, S., Maor, G., Amit, M., Itskovitz‐Eldor, J., Skorecki, K. L., & Tzukerman, M. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1691 · Cited by 906
Clinical pancreatic islet transplantation
Shapiro, A. M. J., Pokrywczyńska, M., & Ricordi, C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.178 · Cited by 773
Improvement in outcomes of clinical islet transplantation: 1999–2010
Barton, F. B., Rickels, M. R., Alejandro, R., Hering, B. J., Wease, S., Naziruddin, B., Oberholzer, J., Odorico, J. S., Garfinkel, M. R., Levy, M., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0063 · Cited by 725
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Single-Donor, Marginal-Dose Islet Transplantation in Patients With Type 1 Diabetes
Hering, B. J. (2005) · JAMA · doi:10.1001/jama.293.7.830 · Cited by 595
Rezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582
Self-citationCharting cellular identity during human in vitro β-cell differentiation
Veres, A., Faust, A. L., Bushnell, H. L., Engquist, E. N., Kenty, J. H.-R., Harb, G., Poh, Y.-C., Sintov, E., Gürtler, M., Pagliuca, F. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1168-5 · Cited by 552
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Schulz, T. C., Young, H. Y., Agulnick, A. D., Josephine Babin, M., Baetge, E. E., Bang, A. G., Bhoumik, A., Cepa, I., Cesario, R. M., Haakmeester, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037004 · Cited by 437
Shapiro, A. M. J., Thompson, D., Donner, T. W., Bellin, M. D., Hsueh, W., Pettus, J., Wilensky, J., Daniels, M., Wang, R. M., Brandon, E. P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100466 · Cited by 313
Self-citationRezania, A., Bruin, J. E., Xu, J., Narayan, K., Fox, J., O'Neil, J., & Kieffer, T. (2013) · Stem Cells · doi:10.1002/stem.1489 · Cited by 269
Self-citationBruin, J. E., Rezania, A., Xu, J., Narayan, K., Fox, J. K., O’Neil, J. J., & Kieffer, T. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2955-4 · Cited by 216
Self-citationMAFA controls genes implicated in insulin biosynthesis and secretion
Wang, H., Brun, T., Kataoka, K., Sharma, A. J., & Wollheim, C. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0490-2 · Cited by 208
Zaunders, J. J., Munier, C. M. L., Seddiki, N., Pett, S. L., Ip, S., Bailey, M., Xu, Y., Brown, K., Dyer, W. B., Kim, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803548 · Cited by 184
Production of Functional Glucagon-Secreting α-Cells From Human Embryonic Stem Cells
Rezania, A., Riedel, M. J., Wideman, R., Karanu, F., Ao, Z.-L., Warnock, G., & Kieffer, T. (2010) · Diabetes · doi:10.2337/db10-0573 · Cited by 184
Self-citationWarnock, G. L., Thompson, D. M., Meloche, R. M., Shapiro, R. J., Ao, Z., Keown, P. A., Johnson, J. D., Verchere, C. B., Partovi, N., Begg, I. S., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190b052 · Cited by 158
Self-citationGottlieb, P. A., Quinlan, S. C., Krause-Steinrauf, H. J., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D., Moran, A., Lachin, J. M., Skyler, J. S., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1349 · Cited by 157
MafA is critical for maintenance of the mature beta cell phenotype in mice
Nishimura, W., Takahashi, S., & Yasuda, K. (2014) · Diabetologia · doi:10.1007/s00125-014-3464-9 · Cited by 136
Shapiro, A. M. J. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.385 · Cited by 134
Haller, M. J., Long, S. A., Blanchfield, L., Schatz, D., Skyler, J. S., Krischer, J. P., Bundy, B. N., Geyer, S. M., WARNOCK, M. V., Miller, J. L., et al. (2019) · Diabetes · doi:10.2337/db19-0057 · Cited by 134
Neurogenin3: A master regulator of pancreatic islet differentiation and regeneration
Rukstalis, J. M., & Habener, J. F. (2009) · Islets · doi:10.4161/isl.1.3.9877 · Cited by 131
β-Cell Function Following Human Islet Transplantation for Type 1 Diabetes
Rickels, M. R., Schutta, M. H., Markmann, J. F., Barker, C. F., Naji, A., & Teff, K. L. (2005) · Diabetes · doi:10.2337/diabetes.54.1.100 · Cited by 129
Greenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 121
Jeyam, A., Colhoun, H., McGurnaghan, S., Blackbourn, L., McDonald, T. J., Palmer, C. N. A., McKnight, J. A., Strachan, M. W. J., Patrick, A. W., Chalmers, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-0567 · Cited by 118
Henry, R. R., Pettus, J., Wilensky, J. S., Shapiro, A. M. J., Senior, P. A., Roep, B. O., Wang, R., KROON, E. J., SCOTT, M., D’Amour, K. A., et al. (2018) · Diabetes · doi:10.2337/db18-138-or · Cited by 111
Hafiz, M. M., Faradji, R., Froud, T., Pileggi, A., Baidal, D., Cure, P., Ponte, G., Poggioli, R., Cornejo, A., Messinger, S., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000187881.97068.77 · Cited by 111
Islet Encapsulation: Physiological Possibilities and Limitations
Korsgren, O. (2017) · Diabetes · doi:10.2337/db17-0065 · Cited by 98
Regenerative medicine and cell-based approaches to restore pancreatic function
Ellis, C. E., Ramzy, A., & Kieffer, T. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.93 · Cited by 92
Self-citationGitelman, S. E., Gottlieb, P. A., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M. E., Moore, W. V., Pinckney, A., Keyes-Elstein, L., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3917-4 · Cited by 90
Hare, K. J., Vilsbøll, T., Holst, J. J., & Knop, F. K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00700.2009 · Cited by 85
Robert, T., Mesmaeker, I. D., Stangé, G. M., Suenens, K. G., Ling, Z., KROON, E. J., & PIPELEERS, D. G. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.040 · Cited by 79
Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors
Memon, B., & Abdelalim, E. M. (2020) · Cells · doi:10.3390/cells9020283 · Cited by 75
Bruin, J. E., Asadi, A., Fox, J., Erener, S., Rezania, A., & Kieffer, T. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.013 · Cited by 72
Self-citationHypothyroidism Impairs Human Stem Cell–Derived Pancreatic Progenitor Cell Maturation in Mice
Bruin, J. E., Saber, N., O’Dwyer, S. M., Fox, J. K., Mojibian, M., Arora, P., Rezania, A., & Kieffer, T. J. (2016) · Diabetes · doi:10.2337/db15-1439 · Cited by 39
Self-citationAsadi, A., Bruin, J. E., & Kieffer, T. J. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415576541 · Cited by 34
Self-citationConcise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes
Schulz, T. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0058 · Cited by 31
An arduous journey from human pluripotent stem cells to functional pancreatic β cells
Loo, L. S. W., Lau, H. H., Jasmen, J., Lim, C. S., & Teo, A. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.12996 · Cited by 30
Iworima, D. G., Rieck, S., & Kieffer, T. J. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.21-0161 · Cited by 25
Self-citationA Simple Method to Replace Islet Equivalents for Volume Quantification of Human Islets
Ramachandran, K., Huang, H.-H., & Stehno‐Bittel, L. (2014) · Cell Transplantation · doi:10.3727/096368914x681928 · Cited by 25
Faleo, G., Lee, K., Nguyen, V., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001146 · Cited by 17
β-Cell Replacement Strategies: The Increasing Need for a “β-Cell Dogma”
Vieira, A., Druelle, N., Avolio, F., Napolitano, T., Sanz, S. N., Silvano, S., & Collombat, P. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00075 · Cited by 16
Cook, L. E., Rees, W. D., Wong, M. Q., Kwok, W. W., Levings, M. K., & Steiner, T. S. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.043 · Cited by 16
Self-citationUitbeijerse, B. S., Nijhoff, M. F., Sont, J. K., & de Koning, E. J. P. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16135 · Cited by 11
Nowacka-Cieciura, E., Karakulska‐Prystupiuk, E., Żuk-Wasek, A., Lisik, W., Basak, G. W., & Durlik, M. (2020) · Transplantation Proceedings · doi:10.1016/j.transproceed.2020.01.127 · Cited by 10
Flagged first, then by citations
Cited by
Sorted by citations
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 472
Shapiro, A. M. J., Thompson, D., Donner, T. W., Bellin, M. D., Hsueh, W., Pettus, J., Wilensky, J., Daniels, M., Wang, R. M., Brandon, E. P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100466 · Cited by 313
Self-citationDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 350
Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes
Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.002 · Cited by 210
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell stem cell · doi:10.1016/j.stem.2024.12.005 · Cited by 233
Metadata
- Authors
- Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., & Kieffer, T. J.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Kieffer, Timothy J.
- ORCID
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 28
- Issue
- 12
- Pages
- 2047-2061.e5
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W3214753991
- Cited by
- 342
- References
- 55
- Citations by year
- 2026: 46 · 2025: 75 · 2024: 75 · 2023: 66 · 2022: 76 · 2021: 3
- FWCI
- 51.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell stem cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Stem Cell Network
- California Institute for Regenerative Medicine
- Juvenile Diabetes Research Foundation United States of America
- BC Children’s Hospital
- Juvenile Diabetes Research Foundation Canada
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- type 1 diabetes, pluripotent stem cells, cell therapy, macroencapsulation, C-peptide secretion, glucose-dependent insulin secretion, beta cell differentiation, regulatory T cells, immunosuppression, graft safety, amylin, MafA
- MeSH terms
- C-Peptide, Cell Differentiation, Diabetes Mellitus, Type 1, Endoderm, Glucose, Humans, Insulin, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
